Topics
Glioblastoma | Treatment | Clinical trials | Antiepileptic Drugs
Home > Publications > Topics > Glioblastoma > Treatment > Clinical trials > Antiepileptic Drugs
Heuer S, Burghaus I, Gose M,
Kessler T, Sahm F, Vollmuth P, Venkataramani V, Hoffmann D,
Schlesner M, Ratliff M, Hopf C, Herrlinger U, Ricklefs F, Bendszus
M, Krieg SM, Wick A, Wick W, Winkler F.
PerSurge
(NOA-30) phase II trial of perampanel treatment around surgery in
patients with progressive glioblastoma.
BMC
Cancer. 2024 Jan
26;24(1):135. doi:
10.1186/s12885-024-11846-1. PMID:
38279087. Interventional
study protocol. ˍ
Thavaneswaran S, Sim HW, Grady J, Espinoza D, Huang ML, Lin F,
McGrath M, Desai J, Charakidis M, Brown M, Kansara M, Simes J,
Thomas D.
A phase II trial of
larotrectinib in tumors with NTRK fusions or extremes of NTRK mRNA
overexpression identified by comprehensive genomic profiling.
Oncologist.
2024 Dec 25:oyae339. doi:
10.1093/oncolo/oyae339. PMID:
39720993. Interventional study. ˍ
Dasgupta A, Mani S, Chatterjee A,
Kannan S, Moiyadi A, Shetty P, Singh V, Menon N, Sahu A, Choudhary
A, Bhattacharya K, Puranik A, Dev I, Epari S, Sahay A, Shah A,
Bano N, Shaikh F, Gupta T.
Study
protocol of short versus long-term levetiracetam in brain tumors
(LIBRA): a phase 3 randomized controlled trial.
BMC
Cancer. 2025 May
21;25(1):911. doi:
10.1186/s12885-025-14305-7. PMID:
40399827. Interventional study protocol. ˍ
Eschen JT, Jensen LL, Hausmann D, Lind ANR, Lukacova S,
Weischenfeldt J, Lassen U, Westphal M, Winkler F, Simonsen U,
Korshoej AR.
SENIPERA Phase 0/1
randomized window-of-opportunity clinical trial of SENIcapoc and
PERAmpanel mono- and combination therapy of newly diagnosed
glioblastoma: a trial protocol.
BMC
Cancer. 2026 Apr 14;26(1):667. doi:
10.1186/s12885-026-15784-y. PMID:
41981510. Trial
registration ID: EU-CT: 2025–522605-37–00.
ˍ